Ascendis Pharma A (ASND) Payables (2012 - 2026)
Ascendis Pharma A (ASND) posted Payables of $616.7 million for Q1 2026, up 1.87% sequentially from $605.4 million in Q4 2025, and up 9.81% YoY from $561.6 million in Q1 2025.
Ascendis Pharma A (ASND) Payables (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Payables for 15 years, with the latest figure at $616.7 million in Q1 2026.
- Quarterly Payables rose 9.81% year-over-year to $616.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $616.7 million (up 9.81% YoY) and the FY2025 annual result came in at $605.4 million, up 2.15% from the prior year.
- Payables climbed to $616.7 million in Q1 2026 per ASND's latest filing, from $605.4 million in the prior quarter.
- Over five years, Payables peaked at $730.5 million in Q3 2023 and troughed at $498.5 million in Q4 2022.
- A 5-year average of $596.8 million and a median of $592.6 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2024: Payables surged 1048.72% in 2022, then declined 25.23% in 2024.
- Over 5 years, Payables stood at $498.5 million in 2022, then grew by 8.28% to $539.8 million in 2023, then rose by 9.8% to $592.6 million in 2024, then rose by 2.15% to $605.4 million in 2025, then rose by 1.87% to $616.7 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $616.7 million, $605.4 million, and $590.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 616.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 616.71 Mn |
| Dec 31, 2025 | 605.36 Mn |
| Sep 30, 2025 | 590.19 Mn |
| Jun 30, 2025 | 579.33 Mn |
| Mar 31, 2025 | 561.63 Mn |
| Dec 31, 2024 | 592.64 Mn |
| Sep 30, 2024 | 546.18 Mn |
| Jun 30, 2024 | 572.60 Mn |
| Mar 31, 2024 | 564.38 Mn |
| Dec 31, 2023 | 539.76 Mn |
| Sep 30, 2023 | 730.48 Mn |
| Jun 30, 2023 | 654.98 Mn |
| Mar 31, 2023 | 656.27 Mn |
| Dec 31, 2022 | 498.48 Mn |
| Sep 30, 2022 | 624.37 Mn |
| Jun 30, 2022 | 611.55 Mn |
| Mar 31, 2022 | 600.92 Mn |
| Dec 31, 2021 | 180.04 Mn |
| Sep 30, 2021 | 90.18 Mn |
| Jun 30, 2021 | 53.24 Mn |